Harpoon’s McMahon becomes CEO at Storm
Plus new CFO, CSO at Voyager and updates from Sonoma, Garuda, Alloy, Homology and more
Storm Therapeutics Ltd. hired Jerry McMahon as CEO. McMahon was president and CEO of Harpoon Therapeutics Inc. (NASDAQ:HARP) from 2016 to 2021, and previously president and CEO of Kolltan Pharmaceuticals Inc. Storm is developing small molecules targeting RNA-modifying enzymes; the company said it had filed an IND for its METTL3 inhibitor STC-15 and that, if the IND is approved, STC-15 would the first inhibitor of an RNA-modifying enzyme to enter clinical testing in humans.
Gene therapy and neuroscience company Voyager Therapeutics Inc. (NASDAQ:VYGR) hired Peter Pfreundschuh as CFO, Todd Carter as CSO and Trista Morrison as SVP of corporate affairs. Pfreundschuh was CFO at Frequency Therapeutics Inc. (NASDAQ:FREQ), Carter was SVP of research at Voyager, and Morrison was chief corporate affairs officer at Saniona AB (SSE:SANION). Voyager announced a restructuring in February that included the appointment of Biogen Inc. (NASDAQ:BIIB) veteran Alfred Sandrock to the company’s board; Sandrock is now the company’s CEO. ...